Comparison of bolus remifentanil versus bolus fentanyl for induction of anesthesia and tracheal intubation in patients with cardiac disease

Drug‐administration sequence of target‐controlled propofol and remifentanil influences the onset of rocuronium. A double‐blind, randomized trial

“…However, remifentanil is known to cause bradycardia and hypotension . Joo et al . reported that systolic arterial pressure, HR, central venous pressure, and systemic vascular resistance index were decreased before intubation when remifentanil was administrated as bolus during the induction of anesthesia.…”

Management of the airway without the use of neuromuscular blocking agents: the use of remifentanil

“…Remifentanil combined either with propofol or with inhaled anesthetic agents has been proved to provide acceptable intubating conditions. It is also known that it provides greater haemodynamic stability during inhaled or total intravenous anesthesia, compared to other opioids [15][16][17][18] in healthy adults, as well as in patients with cardiac disease [19] and in children [20,21]. Strong evidence exists that illuminates the usefulness of the drug in cases of difficult airway as well as in neuromuscular diseases.…”

“…In a very recent study, Cafiero et al recommended the use of remifentanil infusion (0.25 lg/kg/min) in patients with risk factors for dysrhythmias, as it prevents the increase in the QT (the distance between the beginning of the QRS wave and the end of the T wave in the electrocardiography) dispersion after intubation in comparison with fentanyl [14]. It is also known that it provides greater haemodynamic stability during inhaled or total intravenous anesthesia, compared to other opioids [15][16][17][18] in healthy adults, as well as in patients with cardiac disease [19] and in children [20,21]. Finally, as it concerns the use of remifentanil during pregnancy, a rapid transplacental transfer of the drug has been documented [22].…”

Remifentanil and Other Opioids

“…This is probably related to the very rapid onset of effect the drug (Nieuwenhuijs et al 2003;Habib et al 2002;Dimitriou et al 2006;Lecomte et al 2006;Bilgin et al 2006;Chanavaz et al 2005;Locala et al 2005;Pleym et al 2004;Ouattara et al 2004;Godet et al 2004;Heijmans et al 2004;Joo et al 2004;Unlugenc et al 2003;Jellish et al 2003;Manyam et al 2006;Albertin et al 2006;Mustola et al 2005;Albertin et al 2004;Bouillon et al 2004;Kern et al 2004;Drover et al 2004;Mertens et al 2003;Milne et al 2003;Fechner et al 2003;Criado and Gomez e Segura 2003;Bothtner et al 2002).…”